The latest price target for Larimar Therapeutics (NASDAQ:LRMR) was reported by Guggenheim on March 25, 2025. The analyst firm set a price target for $26.00 expecting LRMR to rise to within 12 months (a possible 965.88% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Larimar Therapeutics (NASDAQ:LRMR) was provided by Guggenheim, and Larimar Therapeutics reiterated their buy rating.

The last upgrade for Larimar Therapeutics Inc happened on November 17, 2023 when Citigroup raised their price target to $4.5. Citigroup previously had a neutral for Larimar Therapeutics Inc.

There is no last downgrade for Larimar Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Larimar Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Larimar Therapeutics was filed on March 25, 2025 so you should expect the next rating to be made available sometime around March 25, 2026.

While ratings are subjective and will change, the latest Larimar Therapeutics (LRMR) rating was a reiterated with a price target of $26.00 to $26.00. The current price Larimar Therapeutics (LRMR) is trading at is $2.44, which is out of the analyst’s predicted range.